Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 100% Improvement Relative Risk Ventilator free days 48% primary Ventilation time 38% ICU free days 43% ICU time 38% GI complications while ve.. 78% c19ivm.org Shimizu et al. Ivermectin for COVID-19 LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 88 patients in Japan (December 2020 - May 2021) Lower mortality (p=0.001) and ventilation (p=0.027) Shimizu et al., J. Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024 Favors ivermectin Favors control
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis
Shimizu et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024
Shimizu et al., Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free.., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 88 ventilated COVID-19 patients in Japan, 39 treated with ivermectin within 3 days of admission, showing significantly reduced incidence of GI complications and mortality, and increased ventilator-free days with treatment.
risk of death, 99.9% lower, HR 0.001, p < 0.001, treatment 0 of 39 (0.0%), control 8 of 49 (16.3%), NNT 6.1, adjusted per study, Cox proportional hazard regression.
ventilator free days, 47.9% lower, OR 0.52, p = 0.03, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, primary outcome, RR approximated with OR.
ventilation time, 38.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
ICU free days, 42.8% lower, OR 0.57, p = 0.06, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, RR approximated with OR.
ICU time, 37.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
GI complications while ventilated, 77.9% lower, RR 0.22, p = 0.03, treatment 39, control 49, adjusted per study, Cox proportional hazard regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shimizu et al., 31 Dec 2021, retrospective, Japan, peer-reviewed, 11 authors, study period December 2020 - May 2021, dosage 200μg/kg days 1, 14.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Journal Pre-proof Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis Kentaro Shimizu, Haruhiko Hirata, Daijiro Kabata, Natsuko Tokuhira, Moe Koide, Akiko Ueda, Jotaro Tachino, Ayumi Shintani, Akinori Uchiyama, Yuji Fujino, Hiroshi Ogura PII: S1341-321X(21)00360-3 DOI: https://doi.org/10.1016/j.jiac.2021.12.024 Reference: JIC 1790 To appear in: Journal of Infection and Chemotherapy Received Date: 18 September 2021 Revised Date: 11 November 2021 Accepted Date: 26 December 2021 Please cite this article as: Shimizu K, Hirata H, Kabata D, Tokuhira N, Koide M, Ueda A, Tachino J, Shintani A, Uchiyama A, Fujino Y, Ogura H, Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis, Journal of Infection and Chemotherapy (2022), doi: https://doi.org/10.1016/ j.jiac.2021.12.024. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. (Title Page) 1) Title Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis oo f 2) Author names and affiliations re -p r (Authors) Kentaro Shimizu1, shimiken@hp-emerg.med.osaka-u.ac.jp lP Haruhiko Hirata2, charhirata@imed3.med.osaka-u.ac.jp ur na Daijiro Kabata3, kabata.daijiro@med.osaka-cu.ac.jp Natsuko Tokuhira4, tokuhira@hosp.med.osaka-u.ac.jp Jo Moe Koide4, koide@hosp.med.osaka-u.ac.jp Akiko Ueda5, aueda@hp-lab.med.osaka-u.ac.jp Jotaro Tachino1, jotarotachino@hp-emerg.med.osaka-u.ac.jp Ayumi Shintani, ayumi.shintani@gmail.com Akinori Uchiyama4, auchiyama@hp-icu.med.osaka-u.ac.jp Yuji Fujino4, fujino@anes.med.osaka-u.ac.jp Hiroshi Ogura1, ogura@hp-emerg.med.osaka-u.ac.jp (Affiliations) 1 1 Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2 Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University 2-2 Yamadaoka, Suita 565-0871, Japan 3 oo f Department of Medical Statistics, Osaka City University Graduate School of Medicine, 1-4-3, 4 re -p r Asahimachi, Abeno-ku, Osaka, 545-0051, Japan Intensive Care Unit, Osaka University Hospital, Osaka University, Japan lP 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan 5 ur na Laboratory for Clinical Investigation, Osaka University Hospital, Osaka University, Japan Jo 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan 3) Corresponding author: Kentaro Shimizu, M.D. Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita-city, Osaka..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit